Form 8-K - Current report:
SEC Accession No. 0001213900-26-063125
Filing Date
2026-06-01
Accepted
2026-06-01 06:20:20
Documents
11
Period of Report
2026-05-22
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0292693-8k_moonlake.htm   iXBRL 8-K 37762
  Complete submission text file 0001213900-26-063125.txt   202375

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE mltx-20260522.xsd EX-101.SCH 3020
3 XBRL LABEL FILE mltx-20260522_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE mltx-20260522_pre.xml EX-101.PRE 22362
14 EXTRACTED XBRL INSTANCE DOCUMENT ea0292693-8k_moonlake_htm.xml XML 3083
Mailing Address DORFSTRASSE 29 ZUG V8 6300
Business Address DORFSTRASSE 29 ZUG V8 6300 41 41 510 8022
MoonLake Immunotherapeutics (Filer) CIK: 0001821586 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39630 | Film No.: 261047013
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)